The Technology

The use of Prommune’s lead immune stimulatory candidate, HISPTM, to engage/activate antigen presenting cells (monocytes, macrophages, and dendritic cells) and, consequently, awaken natural immune responses provides a broad platform technology that allows for:

  • Treatment of normal and antibiotic-resistant infections
  • Enhancement of the wound healing process
  • Rapid generation of new vaccines for use in veterinary and human medicine application
  • Enhancement of the effectiveness of existing vaccines

 

 

Prommune, Inc. © 2017